v3.26.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2025
Dec. 31, 2024
Current assets    
Cash and cash equivalents $ 374 $ 7,141
Accounts receivable 3  
Research and development tax credit receivable 549 519
Prepaid expenses and other current assets 575 849
Total current assets 1,501 8,509
Property, plant and equipment, net 180 269
Right-of-use assets, net 607 120
Other assets, non-current   6
Total assets 2,288 8,904
Current liabilities    
Accounts payable and accrued expenses 4,603 1,791
Lease liabilities, current 271 47
Notes payable, current 928  
Other current liabilities 108 450
Total current liabilities 5,910 2,288
Lease liabilities, non-current 312 25
Total liabilities 6,222 2,313
Contingencies (Note 7)
Stockholders' (deficit) / equity:    
Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized, 0 and 856 shares issued and outstanding, at December 31, 2025 and December 31, 2024, respectively
Common stock, par value $0.0001 per share, 300,000,000 shares authorized, 6,836,689 and 3,590,217 shares issued and outstanding, at December 31, 2025 and December 31, 2024, respectively 1  
Additional paid-in capital 124,772 122,316
Accumulated other comprehensive loss (3,578) (1,105)
Accumulated deficit (125,129) (114,620)
Total stockholders' (deficit) / equity (3,934) 6,591
Total liabilities and stockholders' (deficit) / equity $ 2,288 $ 8,904

Source

HTML PDF
ZIP